Recombinant human neuregulin-1 beta - Zensun

Drug Profile

Recombinant human neuregulin-1 beta - Zensun

Alternative Names: Neucardin; rhNRG-1 - Zensun

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zensun
  • Developer Zensun (Shanghai) Sci & Tech
  • Class Anti-ischaemics; Glycoproteins; Heart failure therapies; Neuregulins; Peptide fragments
  • Mechanism of Action Neuregulin-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Chronic heart failure

Most Recent Events

  • 09 Jan 2018 Zensun plans a phase III trial for Chronic Heart Failure in China (NCT03388593)
  • 26 Jun 2015 Recombinant human neuregulin-1 beta is still in phase-II development for Chronic heart failure in USA (SC)
  • 14 May 2013 Safety and efficacy data from phase II trials in Chronic heart failure released by Zensun
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top